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Abstract
We describe methods and issues that are relevant to the measurement of change in tumor uptake of 18F-
fluorodeoxyglucose (FDG) or other radiotracers, as measured from positron emission tomography/computed tomog-
raphy (PET/CT) images, and how this would relate to the establishment of PET/CT tumor imaging as a biomarker of
patient response to therapy. The primary focus is on the uptake of FDG by lung tumors, but the approach can be
applied to diseases other than lung cancer and to tracers other than FDG. The first issue addressed is the sources of
bias and variance in the measurement of tumor uptake of FDG, and where there are still gaps in our knowledge.
These are discussed in the context of measurement variation and how these would relate to the early detection
of response to therapy. Some of the research efforts currently underway to identify the magnitude of some of these
sources of error are described. In addition, we describe resources for these investigations that are being made avail-
able through the Reference Image Database for the Evaluation of Response project. Measures derived from PET
image data that might be predictive of patient response as well as the additional issues that each of these metrics
may encounter are described briefly. The relationship between individual patient response to therapy and utility for
multicenter trials is discussed. We conclude with a discussion of moving from assessing measurement variation to
the steps necessary to establish the efficacy of PET/CT imaging as a biomarker for response.
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Introduction: Lung Cancer, Assessment of
Treatment Response with Positron Emission
Tomography/Computed Tomography
Anatomical imaging with x-ray computed tomography (CT) scanners
using the Response Evaluation Criteria in Solid Tumors [1] is the stan-
dard technique for evaluating the response of lung cancer to most ther-
apies. The benefits and limitations of this approach are discussed
elsewhere in this issue in the article by McNitt-Gray et al. [2]. Imaging
of lung cancer with combined positron emission tomography (PET)
and CT scanners has recently become a standard component of oncol-
ogy diagnosis and staging [3]. In particular, PET/CT imaging of 18F-
fluorodeoxyglucose (FDG) uptake allows more accurate detection of
both nodal and distant forms of metastatic disease [4], and tumor stage
is still the most important prognostic factor for predicting the survival
of patients with non–small cell lung cancer [5], the most common
form of lung cancer. Furthermore, with the development of cytostatic
therapies, metabolic status may be a better indicator of response than
Address all correspondence to: Paul E. Kinahan, PhD, Professor of Radiology, Bio-
engineering and Electrical Engineering, Director, PET/CT Physics, University of
Washington, 222 Old Fisheries Center (FIS), Box 357987, Seattle, WA 98195-7987.
E-mail: kinahan@u.washington.edu
1This work was supported by US National Cancer Institute contract number 24XS036-
004 (RIDER), US National Institutes of Health under grant numbers CA74135
and CA115870, and a Society of Nuclear Medicine Student Fellowship awarded to
Robert Doot.
Received 15 August 2009; Revised 15 August 2009; Accepted 17 August 2009
Copyright © 2009 Neoplasia Press, Inc.
1944-7124 DOI 10.1593/tlo.09223
www.transonc.com
Trans la t iona l Onco logy Volume 2 Number 4 December 2009 pp. 223–230 223
Open access under CC BY-NC-ND license.
anatomical size changes [6]. For these reasons, and the urgent need for
more effective therapies, PET/CT oncology imaging is being increas-
ingly used for quantitative assessment of individual response to therapy
and for clinical trials of novel lung cancer therapies.
Although PET imaging has the potential to produce quantitatively
accurate images of tracer uptake, there is often an unknown global bias.
This is likely a consequence of the primary role of PET imaging, which
is clinical diagnosis and staging of cancer. For this purpose, it is the
relative image fidelity that is of paramount importance. As stated by
Coleman in a 2002 editorial [7].
The answer to the question “Is quantitation necessary for clinical
oncological PET studies interpreted by physicians with experi-
ence in interpreting PET images?” is “no.” Can quantitation be
useful in interpreting clinical PET images for the inexperienced
observer? The answer is “yes.” Image quantitation will become
increasingly important in determining the effect of therapy in
many malignancies.
Whereas the staging studies used routinely in clinical practice may
not depend on accurate image quantification, quantitative measures are
essential for the assessment of therapeutic response [8,9]. While incon-
sistent and non-optimized image quantification has a limited impact on
the interpretation of staging FDG PET/CT scans in clinical practice,
improper image quantification seriously degrades the utility of FDG
PET as a dynamic measure in cancer therapy trials. The disconnection
between the use of PET for clinical imaging and its unrealized potential
for clinical trials is a point of considerable frustration for both imagers
and oncologists [6].
Now, however, there are compelling reasons to understand and
improve the quantitative accuracy of PET imaging. As noted above,
there is a role for quantitative accuracy of measurements from PET
images to determine response to therapy. In addition to CT imaging,
pharmaceutical companies are now using quantitative PET/CT im-
aging to evaluate potential therapies. At the clinical level, the relative
tracer uptake by a lesion, called the standardized uptake value (SUV), is
now routinely reported. If the SUVof a lesion is reported, it is reason-
able to expect that this is an accurate value, or at least that its precision
and variance are understood.
In this article, we review the modality-specific factors that distinguish
PET from CTand magnetic resonance imaging (MRI), what is known
about the bias and variability of PET scanner measurements, both
singly and in multicenter combinations, as well as the overall impact
on multicenter trials. We summarize contributions made to the Refer-
ence Image Database for the Evaluation of Response (RIDER) project
as well as some efforts by other groups. We conclude with a brief analy-
sis of what links are missing in the chain of data acquisition and analysis
of quantitative PET data used for clinical trials and the assessment of
response to therapy.
Measurement Issues Specific to PET/CT
Imaging Characteristics of FDG PET/CT
The fundamental role of a PET/CT scanner is to form an image of
the spatially varying concentration of positron emitters, for example, 18F.
With a half-life of 110 minutes, 18F is favorable in the time scale of
production and the ratio of patient radiation dose to image signal-to-
background noise ratio, too. A positron emitter is attached to a biologic
substrate of interest, for example, the glucose analog deoxyglucose, to
become the radiolabeled tracer FDG. The use of FDG for oncology
imaging accounts for approximately 90% of all PET/CT imaging
procedures. The effectiveness of FDG stems from it being essentially
“trapped” in the glycolytic pathway after the early step of phosphoryla-
tion by the enzyme hexokinase. Phosphorylated FDG does not cross
cellular membrane barriers owing to the negative charge of the added
phosphate group and is not further metabolized by glycolytic enzymes
owing to structural differences between FDG and glucose. Thus, the
rate of accumulation of FDG conveys information about the rate of
glucose metabolism. Because cancer generally has a higher glucose
metabolism than surrounding normal tissue [10], FDG is useful in
cancer detection and staging. Furthermore, changes in measured FDG
accumulation have been shown to be useful as a biomarker for mecha-
nistic effects in response to therapy [6]. As a result, FDG imaging with
PET is increasingly being used to guide therapy [11] and as an indicator
of response in clinical trials [12,13], although more data on the impact
on patient outcomes are still needed [6,8,9].
With corrections for physical effects, notably attenuation and the
detection of scattered and random coincidences, accurate estimates of
the spatially varying concentration of positron emitters (e.g., FDG) can
be obtained. Typical measured units are kilobecquerel per milliliter.
The measured concentration, on average, depends on the amount of
activity injected and volume of distribution (e.g., patient size). To ac-
count for variations in the injected dose and patient size, generally pre-
ferred units are SUVs defined as SUV = R/(D′/V˜ ) where R (kBq/ml)
is the activity concentration at each point), D′ (kBq) is the decay-
corrected injected dose, and V˜ is a surrogate for the true volume of dis-
tribution of tracer inside the body. Typically, patient weight (g) is used
as a surrogate for the volume of distribution, in which case the SUV
units are grams per milliliter. Because adipose tissue, with the exception
of brown fat, does not normally take up significant amounts of FDG,
the estimated lean body mass [14] or body surface area [15] is some-
times used instead of weight.
With proper calibration, and if data corrections (attenuation and
scatter, etc.) are working properly, the reconstructed PET image repre-
sents a quantitatively accurate map of FDG concentration, which in
turn is related to relative metabolic activity, that is, a functional image.
In contrast, a CT image provides an accurate anatomical image. In a
combined PET/CTscanner, the CT image provides precise localization
of regions of FDG uptake, significantly aiding interpretation. The com-
bination has proven so successful that no PET-only scanners used in
oncology imaging are now manufactured [16].
The physics of the detection process and consequent scanner designs
dictate that PET has good positional accuracy, like CT, but low spatial
resolution, compared with CT and MRI. Results are PET images that
are relatively blurry. In addition, PETscanner data often suffer fromhigh
degrees of statistical noise, particularly in thicker, that is, obese, patients
and/or with short acquisition durations. To reduce image noise, addi-
tional smoothing is applied, further degrading image resolution and
increasing noise correlations in the PET image. Both of these effects lead
to size-dependent errors in measuring SUVs, that is, as the size of a focal
accumulation, or “hot spot,” decreases, the measured SUV decreases.
This size-dependent loss in accuracy is often called the partial volume
effect or error [17]. With a typical operational resolution (i.e., not the
best possible resolution), objects smaller than 2 to 3 cm are susceptible
to partial volume errors, as discussed below. Another important property
of PET imaging is the high sensitivity, which allows routine measuring
of micromolar and nanomolar amounts of radiotracer. In terms of con-
trast, FDG PET images are mixed in the sense that most normal tissues
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have similar levels of uptake, making it difficult to distinguish different
organs. In some cases, however, biomolecular activities, such as in most
malignant cancers, have a significantly higher level of FDG uptake.
Both of these contrast levels are visible in the PET image of Figure 1.
In summary, and to contrast with the other tomographic medical
imaging methods (ultrasound, CT, MR, and single photon emission
computed tomography), FDG PET images have a high level of sen-
sitivity and very good contrast for most cancers.With proper calibration
and corrections for attenuation, scatter, and other effects, PET images
accurately represent internal tracer concentrations, expressed as SUVs,
which are subject to partial volume errors. In addition, PET images have
very good positional accuracy (i.e., no geometrical distortion as can
happen in ultrasound or MRI) but low positional precision (i.e., the
images have relatively low resolution). The images are typically noisy,
with a high level of noise correlations introduced by image recon-
struction and smoothing [18]. The combination of PET and CT in a
single scanner is particularly felicitous because both modalities have
excellent positional accuracy and provide strongly complementary in-
formation useful in oncology imaging. In addition, the CT image can
be used for attenuation correction of the PET raw data [19], which
shortens overall patient scan times and provides other benefits to the
PET imaging process, as described elsewhere [20].
Bias and Variance in PET/CT Imaging
In the accompanying article by Meyer et al. [21], precise and accu-
rate definitions of variance and bias are given. With respect to PET
imaging, it is possible to use phantoms to accurately measure both fea-
tures, as described below.
For clinical imaging, determining bias becomes a much more chal-
lenging problem due to the lack of ground truth. Less appreciated
perhaps is that it is also very challenging to use phantoms to mimic
or estimate the bias that occurs in clinical scanners owing to the diffi-
culty of constructing test phantoms that accurately represent both the
spatially varying distributions of both radiotracer concentration and
attenuation coefficients. In other words, phantom measurements can
provide a general guide, but without further confirmation, they cannot
be regarded as an accurate representation of bias in clinical imaging.
Variance in clinical imaging can be estimated through the use of
repeat scans where it is assumed that there are no changes in the object
being imaged. At a minimum, repeat scans on patients have shown that
there is a sample SD of approximately 10% to 13% in well-controlled
single-scanner tests and when scanning the same patient (not undergo-
ing therapy) within a few days [22–26]. These are akin to the “coffee-
break” concept where the patient is imaged, takes a short break, and
is reimaged with everything else remaining the same.With PET patient
imaging, however, scans occur at a minimum of a day apart to allow for
complete radioactive decay of the FDG. The variance in this case is the
result of several factors, including variability in the patient, scanner, and
procedures. The same studies also showed that the distribution of dif-
ferences is Gaussian, although this is for the case of no true biologic
change. In the case where there has been true biologic change, there
may be a different distribution and magnitude of differences, as dis-
cussed by Meyer et al. in this issue [21]. Such studies do not address
the variance present in longitudinal studies, where there is true change,
changes in analysis methods, and multicenter studies.
Sources of Bias and Variance in PET/CT Imaging
A comprehensive survey of the many factors that affect bias and/or
variance was recently presented by Boellaard [27]. Here, we summarize
the major components: Scanner related issues, patient related factors,
protocol variations, analysis methods, and interactions between sources
of variance.
Figure 1. Sample images from the RIDER PET/CT collection. Serial coronal sections of PET/CT images of a patient with lung cancer (arrows).
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Scanner components of bias and variance. The major scanner-
specific factors that can increase bias and variance are listed in Table 1.
Note that the amount of bias and variance introduced by physical
effects is a complex interaction between the magnitude of the effect
and the correction steps. For example, contamination of raw data by
random coincidences adds both bias and noise. Two different methods
of estimating the mean levels of random coincidences in the raw
data may have different tradeoffs in accuracy and precision. Finally,
the manner of using the estimates to remove the effect, for example,
simple subtraction versus incorporation in the system model, will also
impact the bias and variance of the estimate of the uncontaminated
raw data.
Several of the effects in Table 1 are characterized by the National
Electrical Manufacturers Association NU-2 standard but only for spe-
cific reference objects and not for different FDG distributions in differ-
ent sized patients. In addition, one notable exception is that there is
no specification for tracking or testing global scaling accuracy.
Global scaling is determined by several factors, the most sensitive of
which is cross-calibration to a known level of activity of 18F-FDG in a
syringe, as measured by a dose calibrator. The FDG is then typically in-
jected into a water-filled cylindrical phantom (20-cm diameter × 20-cm
height), which is then imaged and reconstructed. The correspondence
between the known activity of the syringe and the commensurate mea-
sured activity concentration in the uniform cylinder establishes the
global scaling factor for the scanner. There are, however, several weak
links in this chain, including manual recording of the values (ideally be-
fore and after injection) as well as the time of each activity measurement
andmanual entry of these values into the scanner data system. It is worth
noting that these issues are also relevant for each patient scan, and so
errors can and do occur on individual patient scans as well. A related
approach is to use a long-lived calibration source, typically a 20-cm
cylinder with 68Ge (9-month radioactive half-life) embedded in epoxy.
However, the accuracy of the activity level within the cylinder is typically
±10%, and the necessary cross-calibration with the dose calibrator is not
established. Because global calibration factors are performed periodi-
cally, typically monthly or quarterly as per manufacturers’ recommenda-
tions, every patient scan during the corresponding calibration period
is affected by the new global scaling factor. Figure 2 shows the global
scaling for a PET/CT scanner during a 18-month period indicating a
miscalibration at one point that induced an approximate 25% shift in
overall 18F SUV values.
Another potentially significant error in global scaling is the dose cali-
brator itself. Recently, this has come under increased scrutiny with the
development of an National Institute of Standards and Technology
(NIST)–traceable standard [28]. Initial results indicate an approximate
5% variability within manufacturers and a 10% shift in absolute cali-
bration between the two main manufacturers of dose calibrators [29].
As is the case for the scanner global calibration factor, an error in this
value is a direct multiplier in terms of bias.
The intrinsic detector resolution, that is, sampling, leads to the well-
known partial volume effect, which causes blurring at edges of regions
of different tracer uptake [17]. This effect is increased by smoothing
applied during the reconstruction process to suppress noise. One conse-
quence of this effect is that “hot” objects smaller than approximately
three times the operating resolution have a decreased level of apparent
activity. Conversely, small “cold” regions have higher than true activity
levels. Because clinical resolution levels are on the order of 1 cm, this
means that objects smaller than ∼3 cm typically suffer from this effect.
This is illustrated in Figure 3.
The relationship of quantitative accuracy with scanner quality assur-
ance and control (QA/QC) procedures is often not clear. Manufacturer
QA/QC procedures are generally designed to track a variety of param-
eters to catch changes in scanner performance parameters that will
(hopefully) detect if there is a change in some scanner-operating pa-
rameter, for example, reduced sensitivity and/or increased variations
Table 1. Major Scanner-Specific Factors That Affect Bias and Variance in PET Images.
Global calibration method
Attenuation and correction method
Scattered coincidences and correction method
Random coincidences and correction method
Detector efficiency variations and correction method
Geometrical efficiency normalizations
Intrinsic detector resolution
Sensitivity
Live time as a function of count rate
Image reconstruction method (especially smoothing)
Data processing algorithms, e.g., decay correction
Clock synchronization
Figure 2. (A) Global calibration factor for a clinical PET/CT scanner during an 18-month period. Indicated is an erroneous calibration
factor that was used for approximately one month before detection. Values are indicated for both the standard 18F-FDG calibration
method and using long-lived 68Ge sources showing significant variability. (B) FDG PET images using the median (left image) and the
outlier (right image) global calibration factors. The images are identical except for an overall scale difference in all SUVs of approximately
25%. This type of periodically vulnerable calibration error has clear consequences for longitudinal studies.
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in detector patterns from a uniform source that could indicate failing
components such as a detector module. These changes may or may not
signify a reduction of image quality. One factor that is generally not
tracked, however, is quantitative scaling or accuracy. This arguably im-
portant issue has so far received little attention.
Patient and protocol components of bias and variance. There are
several effects related to the patient and the imaging protocol that
can potentially increase bias and variance in the measurement of
FDG uptake. Four of the more recognized factors are 1) the lesion
size (i.e., susceptibility to partial volume errors), 2) tumor heterogeneity
(e.g., if a tumor has a necrotic center and FDG uptake is localized
to the rim), 3) elevated blood glucose levels (which reduces FDG
uptake), and 4) the uptake time between FDG injection and scan ac-
quisition, as tumor FDG uptake generally increases for several hours.
These factors have been well summarized in several discussions (e.g.,
[30,31]). It is also possible to include image reconstruction protocols
in this category, although we have included it in the prior category be-
cause the choice of parameter settings is coupled to the manufacturer-
dependent algorithm.
Image analysis methods and impact on bias and variance. Several
methods are used to extract SUV values from the reconstruction
images. Typically, a region of interest (ROI) is drawn around a lesion
or area of interest. The method of drawing can vary widely. Typically,
two-dimensional ellipses or circles are drawn in one or more transaxial
images, but three-dimensional shapes can also be used. The size of the
ROI can be determined manually, for example, based on the PET
image and/or the CT image, or set by a thresholding or segmentation
procedure. The range of available methods varies among vendors. Once
the region is set, then the values within the ROI can be considered as
a histogram of SUVs, and one or more derived values can be used to
characterize the distribution. Commonly used methods are the average
and maximum SUV values as well as the “peak” value, which is the
average of a fixed, size ROI (e.g., 15 mm diameter) positioned to obtain
the maximum average value while also including the pixel with the
maximum value. The most commonly used method for clinical imag-
ing is SUVmax, owing in part to its ease of measurement, reproducibil-
ity, and reduced sensitivity to partial volume errors. For the purposes of
measuring response to therapy, however, there is not yet a consensus on
the best method [13,32]. In addition, there have been no efforts to date
to test the reproducibility of SUVs measured on different vendors’ dis-
play stations.
RIDER Supported Investigations into Sources
of Error for FDG PET/CT SUVs
Society of Nuclear Medicine Validation Phantom
The Society of NuclearMedicine (SNM) commissioned a “validation
phantom” for comparing quantitation between different PET imaging
centers and scanner models [33]. The phantom was filled with 68Ge
(271-day half-life) in an epoxy matrix, so that precisely the same object
was imaged on different scanners, with the decay of 68Ge being the
only difference between scans. In addition, the true activity levels were
known to within 10%. As a separate project, the phantom was repeat-
edly rescanned on a GE and Siemens PET/CTscanner [34] and on each
of the three PET/CTscanner manufacturers (GE, Philips, and Siemens)
[35]. Several versions of 20-repeat coffee-break experiments were per-
formed. Images of the phantom and illustrative results are shown in Fig-
ure 3. Many of the data sets have been uploaded to the National Cancer
Imaging Archive (NCIA)–RIDER database in a manner similar to the
patient images described below as resource for comparingmeasurements
made from patient images.
The plot in Figure 3B illustrates several findings. The first is the re-
duction in recovery coefficient (measured SUV/true SUV) with de-
creasing sphere diameter, which is caused by the partial volume error
and image smoothing. The second is the difference between SUVmax
and SUVmean, showing that SUVmax is somewhat less sensitive to partial
volume error, but that there is also a significant change in bias between
the two analysis methods. Third, the coefficient of variation (deter-
mined from 20 repeat scans) is relatively small, albeit larger for SUVmax,
owing to the larger statistical fluctuations in that metric given that it is
based on only one pixel.
Figure 3. Partial volume and variance effects for a single scanner. (A) CT and PET images of the SNM validation phantom. (B) Absolute
recovery coefficient as a function of sphere diameter and method of reporting SUV from an ROI placed over the spheres.
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AAPM/SNM TG145 Calibration Phantom
The SNM validation phantom was not feasible for widespread use
owing to cost, weight, and high levels of radioactivity. In an attempt
to simplify the process, the Task Group 145 “Quantitative PET/CT
Imaging,” sponsored by the American Association of Physicists in
Medicine (AAPM) and the SNM (AAPM/SNM TG145), devised a
modification of the qualification phantom used by the American
College of Radiology (ACR). In this case, four adjacent cylinders with
diameters ranging from 8 to 25 mm were filled with 68Ge/68Ga in an
epoxy matrix, significantly reducing cost, weight, and total radioactivity
levels in the package sent to participants. To date, this phantom has
been imaged at 10 different PET centers and analysis of the intersite
variability of SUV measurements is ongoing [36].
Longitudinal Scanner Calibration Variations
To evaluate longitudinal scanner calibration variations, we evaluated
several years worth of scanner calibration data [37]. The results (e.g.,
Figure 4) indicate 6% to 10% variability if no quality assurance proce-
dures are applied to the calibration process itself. If quality assurance
procedures that catch operator errors are applied, then the variability
drops to 3% to 4%.
Monitoring the calibration process, however, does not include errors
from dose-calibrator measurements, which are used in every patient
scan. Recent results indicate that there is approximately a 7% error
from dose calibrator measurements for 18F [29]. As part of the RIDER
project, we have recently commenced on a multicenter longitudinal
measurement of combined scanner and dose-calibrator effects using
the new NIST standard for 68Ge as a reference for 18F assays [28].
RIDER PET/CT Images
Under institutional review board approval, 30 sets of clinical PET
and 35 sets of PET/CT images of lung cancer patients with one or
more follow-up scans were selected. The software application Field
Center (and later, the Clinical Trial Processor) developed by the Ra-
diological Society of North America (RSNA) was used to deidentify
and transmit the images to the NCIA image database, now called the
National Biomedical Imaging Archive. Sample patient images are
shown in Figure 1.
During verification that image sets could be uploaded and down-
loaded, two issues unique to PET/CTwere resolved. First, for PET/CT
studies, the ability to retrieve concurrent PET and CT image sets was
added to the NCIA. Second, the deidentification process had to be
adjusted to not remove critical timing and other information that is
used for decay correction of the FDG activity levels and SUVs. The
necessary information for SUV calculation is listed in Table 2.
As a final step, a subset of the uploaded images were downloaded and
analyzed for relative changes using a commercial PET/CT display and
analysis package (PET Volume Computed Assisted Reading; GE
Healthcare). There were 10 patients with 20 lesions with two or more
serial scans. Lesions were tracked from scan to scan using display and
analysis software, and several change metrics were recorded. These in-
cluded lesion volume (from the PET image using a 50% threshold),
average SUV, maximum SUV, maximum and average SUV relative to
liver SUV, and total lesion glycolysis, also called metabolic volume,
which is defined as (average SUV) × volume [38]. The changes for each
metric for all 20 lesions are given in Figure 5.
Effects of Bias and Variance in Determining
Response for Clinical Trials
Proposed values reported in the literature for the minimum percent-
age change in PET that reflects true biologic changes between serial
FDG-PETmeasurements range from the 15% to 25% recommended
by the European Organization for Research and Treatment of Cancer
PET Study Group [39] to 20% [25] to 25% [23] to 50% [40] to 55%
[41] and others. A revised definition of these guidelines including
Figure 4. Scanner calibration factors (relative tomean value) during a
4-year period. Datawere collectedwithmanufacturer-recommended
procedures using 18F in a water-filled cylinder (diamonds) and the
same 68Ge in epoxy cylindrical source.
Table 2. Public DICOM Header Fields Necessary for Proper SUV Calculation.
DICOM Tag (Group, Element) Field Name Used For
(0008,0031) Series time Decay correction
(0008,0032) Acquisition time Decay correction
(0010,0040) Patient sex SUV lean body mass
(0010,1020) Patient size SUV lean body mass
(0010,1030) Patient weight SUV
(0018,1072) Radiopharmaceutical start time Decay correction
(0018,1074) Radionuclide total dose SUV
(0018,1075) Radionuclide half-life Decay correction
(0054,1102) Decay correction Decay correction
(0054,1300) Frame reference time Decay correction
(0054,1321) Decay factor Decay correction
(7053,1000) SUV factor SUV (Philips only)
Note that these are relevant for images acquired by GE or Siemens PET/CTscanners. Other necessary
information (e.g., tracer activity) is contained in private fields that are determined by each manu-
facturer. Philips PET/CT scanners use the private field (7053,1000): SUV Factor only.
Figure 5. Sample calculation of change metrics from serial PET/CT
image sets illustrating a potential use of the RIDER collection. Each
symbol represents the change values for an individual lesion for the
difference metrics.
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a 30% threshold has recently been proposed by Wahl et al. [13]. There
are several constraints on the previously published minimum thresholds
for changes in PETmetrics, but the issue relevant for the discussion here
is that these guidelines were based on the best information at the time
of their development, and that they do not necessarily apply to longi-
tudinal studies or multicenter trials, where the variance is greater. This
is shown in Figure 6, which illustrates the impact of overall PETmea-
surement error on required sample size for a range of expected effect
sizes (e.g., ΔSUV). These results were calculated for two-sample t-tests
and designed to yield 80% power at a significance level (α) of 0.05 [35].
As the noise level doubles from 10% to 20%, the needed number of
samples increases more three times for trials that anticipate small effect
sizes. These results indicate that if the true levels of variance are under-
estimated (e.g., owing to increased variance from multicenter compari-
sons), a study runs the risk of not identifying a significant result because
of being underpowered.
Another important consideration is the sensitivity of the selected PET
metric to the anticipated true effect change that is provided to the de-
signer of the clinical trial based, for example, from a nonimaging labo-
ratory experiment. Changes in SUV measurements have been reported
to be less sensitive than changes in dynamic PETmetrics in patients with
low baseline SUVs, that is, below 5-to-1 tumor-to-background ratios, in
breast cancer patients [42,43]. This reduced SUV sensitivity for some
patient populations is due in part to the SUV metric’s inability to sepa-
rate metabolized FDG from unmetabolized background FDG, unlike
more sophisticated PETmetrics derived for kinetic analyses of dynamic
PET scans [9,25,44–46]. The reduced SUV sensitivity impacts trial
design by reducing the observed (or measured) effect size and thereby
increases the required sample size needed to adequately power the clini-
cal trial [35,47].
Determining the true variance of individual patient measures of re-
sponse to therapy has not been completed. There are several effects
discussed here, such as dose-calibrator calibration, intrascanner and in-
terscanner variability, and longitudinal variability that will also affect
multicenter studies. In addition, the effects of intraobserver and inter-
observer variability and display/analysis workstation concordance across
multiple sites have not been determined. Several of these studies are
underway as part of the RIDER project or sponsored by the SNM,
AAPM, American College of Radiology Imaging Network (ACRIN),
and RSNA. In particular, the RIDER project is now focusing on col-
lecting data on multisite longitudinal variability of scanner and dose-
calibrator calibration factors.
Initiatives
In addition to the RIDER project, there are several initiatives specific to
the use of quantitative PET/CT imaging for response to therapy and for
clinical trials. These include (but are not limited to) the publication of
ACRIN PET core laboratory procedures, the recent NIST standard for
68Ge, the RSNA Quantitative Imaging Biomarkers Alliance, the joint
AAPM/SNM Task Group 145: Quantitative PET/CT Imaging
(TG145), the SNM Clinical Trials Network, the NCI-funded Imaging
Response Assessment Teams, and European initiatives. These groups
are working toward the common goal of determining what is known,
what remains to be determined, and what physical standards are feasible
for evaluating response to therapy and for clinical trials.
Conclusions
There is growing evidence that FDG PET/CTmeasures of response to
therapy, even early in the therapeutic regime, are linked to patient out-
comes for several forms of cancer. As well, PET/CT using FDG and
other tracers has been established as a useful tool for mechanistic effects
in drug discovery studies. Given the evolving overall picture of the bias
and variance in single-center and multicenter imaging studies, however,
current studies run the risk of being underpowered. There are several
critical areas where bias and variance and the sensitivity of selected PET
metric to true change should be estimated and included in initial trial
design, including multisite longitudinal variability of scanner and dose-
calibrator calibration factors, as well as data analysis methods and effects
of variations between display/analysis workstations.
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